EVAXION BIOTECH
Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase I/IIa clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections with one program currently in preclinical development against S. aureus (including Methicillin-resistant S. aureus) induced skin and soft tissue infections.
EVAXION BIOTECH
Industry:
Biotechnology
Founded:
2008-01-01
Address:
Copenhagen, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.evaxion-biotech.com
Total Employee:
11+
Status:
Active
Total Funding:
57 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Google Tag Manager Content Delivery Network Google Universal Analytics Google Maps Pound Sterling New Relic
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
PaxVax
PaxVax is a start-up developing candidate oral vaccines for key infectious diseases.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
ProtActivity
ProtActivity focusses on the development of vaccines against protozoal diseases.
Versameb
Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.
Current Employees Featured
Jens Kringelum Director, Genomic Immuno Oncology @ Evaxion Biotech
Director, Genomic Immuno Oncology
2018-01-01
Andreas Holm Mattsson Chief Innovation Officer and Founder @ Evaxion Biotech
Chief Innovation Officer and Founder
2020-09-01
Birgitte Rønø Chief Scientific Officer & Director of Cancer Vaccines @ Evaxion Biotech
Chief Scientific Officer & Director of Cancer Vaccines
2021-09-01
Niels Moeller CBO and founder @ Evaxion Biotech
CBO and founder
2017-08-01
Lars Wegner CEO @ Evaxion Biotech
CEO
2017-06-01
Pär Comstedt Director, Infectious Disease Vaccines @ Evaxion Biotech
Director, Infectious Disease Vaccines
2018-01-01
Founder
Stock Details
Investors List
Lincoln Park Capital Fund
Lincoln Park Capital Fund investment in Post-IPO Equity - Evaxion Biotech
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-21 | Evaxion Biotech Appoints Dr. Birgitte Rønø as Chief Scientific Officer |
Official Site Inspections
http://www.evaxion-biotech.com Semrush global rank: 6.69 M Semrush visits lastest month: 867
- Host name: 76.76.21.21
- IP address: 76.76.21.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Evaxion Biotech"
About Evaxion - Leading AI-Driven Vaccine Development - Evaxion …
Learn how Evaxion leverages AI in vaccine development, and discover our mission, advanced technology, and leadership team committed to improving patient outcomes. ... From 2018 to …See details»
Evaxion Biotech - Crunchbase Company Profile
Evaxion Biotech is devoted to the discovery and development of vaccines against cancer and infectious diseases. New. Resources. Advanced Search. Start …See details»
Press Releases - Evaxion Biotech
The Investor Relations website contains information about Evaxion Biotech's business for stockholders, potential investors, and financial analysts.See details»
Evaxion Biotech 2025 Company Profile: Stock …
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with …See details»
Evaxion Biotech - Funding, Financials, Valuation & Investors
Evaxion Biotech is registered under the ticker NASDAQ:EVAX . Their stock opened with $10.00 in its Feb 4, 2021 IPO. Evaxion Biotech is funded by 5 investors. Merck Global Health Innovation …See details»
Annual Reports | Evaxion Biotech
Be the first to know about news, milestones and events at Evaxion by subscribing to our investor email alerts. Required fields denoted by an asterisk (). Alert type; Event. News. Email. First …See details»
Evaxion Biotech Company Profile - Office Locations, Competitors
Oct 29, 2024 Evaxion Biotech A/S is a company focused on the development of vaccines against cancer and infectious diseases. It discovers antigens and neo-epitopes for vaccines …See details»
Evaxion Biotech | Evaxion Biotech
Jan 20, 2025 Are you eager to deep-dive into Evaxion's business? Download our company presentation below.See details»
Evaxion Announces Successful Completion of the ... - Evaxion …
Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion's proprietary and scalable AI prediction models harness the power of …See details»
Evaxion Biotech - Company info. interviews, news
Jan 26, 2024 Evaxion Biotech Uses AI To Develop Anticancer And Antimicrobial Vaccines Aug. 21, 2017 This is an interview with Niels Iversen Møller, a CEO, and Co-founder of Evaxion Biotech -- an immuno-informatics biotech from …See details»
AI-Immunology™ Powered Vaccines | Evaxion Biotech
With our AI-Immunology™ platform, Evaxion harness the power of the human immune system to create novel immunotherapies for the patients of today and tomorrow. About us. Careers. …See details»
Mission, Vision & Core Values of Evaxion Biotech
Oct 2, 2024 Strategic Partnerships: Evaxion Biotech collaborates with leading academic institutions, research organizations, and pharmaceutical companies to leverage expertise and …See details»
Evaxion Announces Successful Completion of the Initial Phases of ...
Feb 20, 2024 The vaccine development project combines both organizations' unique capabilities and know-how. Evaxion's Chief Executive Officer Christian K ... Feb. 20, 2024 (GLOBE …See details»
Evaxion Biotech A/S Closes Public Offering Raising $10.8 ... - Nasdaq
Jan 31, 2025 Evaxion Biotech A/S announced the successful closing of a public offering of 3,997,361 American Depositary Shares (ADSs) and associated warrants, raising …See details»
Evaxion partnerships | Evaxion Biotech
In September 2023, Evaxion entered a discovery partnership with Afrigen Biologics and the recently created mRNA Vaccine Technology Transfer Hub. The hub was established by the …See details»
Evaxion to present new phase 2 data for AI-designed ... - BioSpace
15 hours ago COPENHAGEN, Denmark, March 25, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI …See details»
Evaxion to present new phase 2 data for AI-designed personalized …
1 day ago COPENHAGEN, Denmark, March 25, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ …See details»
Evaxion Partners With Pharmaceutical Company Afrigen
Sep 20, 2023 The World Health Organization (WHO) has reported an alarming estimate of 82 million new gonorrhea infections occurring annually worldwide with a rise in antibiotic-resistant …See details»
Pipeline - Evaxion’s world-class product candidates - Evaxion Biotech
Whilst checkpoint inhibitors have revolutionized the treatment of melanoma, too many patients still die from this cancer. EVX-01 has shown promising clinical results in, with patients benefitting - …See details»
EVAXION BIOTECH Earnings Preview: Recent $EVAX Insider …
2 days ago EVAXION BIOTECH is expected to release its quarterly earnings data on Tuesday, March 25th after market close, per Finnhub. Analysts are expecting revenue of $1,692,690 …See details»